Report Detail
Global Targeted Therapy for Bladder Cancer Market Growth (Status and Outlook) 2022-2028
- RnM4489279 |
- 02 September, 2022 |
- Global |
- 86 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
The global market for Targeted Therapy for Bladder Cancer is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Targeted Therapy for Bladder Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Targeted Therapy for Bladder Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Targeted Therapy for Bladder Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Targeted Therapy for Bladder Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Targeted Therapy for Bladder Cancer players cover Pfizer, Merck KGaA, Roche, Astellas and Janssen Biotech, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Targeted Therapy for Bladder Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Targeted Therapy for Bladder Cancer market, with both quantitative and qualitative data, to help readers understand how the Targeted Therapy for Bladder Cancer market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Targeted Therapy for Bladder Cancer market and forecasts the market size by Type (Atezolizumab (Tecentriq), Avelumab (Bavencio) and Erdafitinib (Balversa)), by Application (Hospital, Retail Pharmacy and Other,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Segmentation by application
Hospital
Retail Pharmacy
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
Chapter Introduction
Chapter 1: Scope of Targeted Therapy for Bladder Cancer, Research Methodology, etc.
Chapter 2: Executive Summary, global Targeted Therapy for Bladder Cancer market size and CAGR, Targeted Therapy for Bladder Cancer market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Targeted Therapy for Bladder Cancer revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Targeted Therapy for Bladder Cancer revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Targeted Therapy for Bladder Cancer market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer, Merck KGaA, Roche, Astellas, Janssen Biotech, Bristol-Myers Squibb, Merck & Co. and Gilead Sciences, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Targeted Therapy for Bladder Cancer Market Size 2017-2028
- 2.1.2 Targeted Therapy for Bladder Cancer Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 Targeted Therapy for Bladder Cancer Segment by Type
- 2.2.1 Atezolizumab (Tecentriq)
- 2.2.2 Avelumab (Bavencio)
- 2.2.3 Erdafitinib (Balversa)
- 2.2.4 Other
- 2.3 Targeted Therapy for Bladder Cancer Market Size by Type
- 2.3.1 Targeted Therapy for Bladder Cancer Market Size CAGR by Type (2017 VS 2022 VS 2028)
- 2.3.2 Global Targeted Therapy for Bladder Cancer Market Size Market Share by Type (2017-2022)
- 2.4 Targeted Therapy for Bladder Cancer Segment by Application
- 2.4.1 Hospital
- 2.4.2 Retail Pharmacy
- 2.4.3 Other
- 2.5 Targeted Therapy for Bladder Cancer Market Size by Application
- 2.5.1 Targeted Therapy for Bladder Cancer Market Size CAGR by Application (2017 VS 2022 VS 2028)
- 2.5.2 Global Targeted Therapy for Bladder Cancer Market Size Market Share by Application (2017-2022)
3 Targeted Therapy for Bladder Cancer Market Size by Player
- 3.1 Targeted Therapy for Bladder Cancer Market Size Market Share by Players
- 3.1.1 Global Targeted Therapy for Bladder Cancer Revenue by Players (2020-2022)
- 3.1.2 Global Targeted Therapy for Bladder Cancer Revenue Market Share by Players (2020-2022)
- 3.2 Global Targeted Therapy for Bladder Cancer Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Targeted Therapy for Bladder Cancer by Regions
- 4.1 Targeted Therapy for Bladder Cancer Market Size by Regions (2017-2022)
- 4.2 Americas Targeted Therapy for Bladder Cancer Market Size Growth (2017-2022)
- 4.3 APAC Targeted Therapy for Bladder Cancer Market Size Growth (2017-2022)
- 4.4 Europe Targeted Therapy for Bladder Cancer Market Size Growth (2017-2022)
- 4.5 Middle East & Africa Targeted Therapy for Bladder Cancer Market Size Growth (2017-2022)
5 Americas
- 5.1 Americas Targeted Therapy for Bladder Cancer Market Size by Country (2017-2022)
- 5.2 Americas Targeted Therapy for Bladder Cancer Market Size by Type (2017-2022)
- 5.3 Americas Targeted Therapy for Bladder Cancer Market Size by Application (2017-2022)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Targeted Therapy for Bladder Cancer Market Size by Region (2017-2022)
- 6.2 APAC Targeted Therapy for Bladder Cancer Market Size by Type (2017-2022)
- 6.3 APAC Targeted Therapy for Bladder Cancer Market Size by Application (2017-2022)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Targeted Therapy for Bladder Cancer by Country (2017-2022)
- 7.2 Europe Targeted Therapy for Bladder Cancer Market Size by Type (2017-2022)
- 7.3 Europe Targeted Therapy for Bladder Cancer Market Size by Application (2017-2022)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Targeted Therapy for Bladder Cancer by Region (2017-2022)
- 8.2 Middle East & Africa Targeted Therapy for Bladder Cancer Market Size by Type (2017-2022)
- 8.3 Middle East & Africa Targeted Therapy for Bladder Cancer Market Size by Application (2017-2022)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Targeted Therapy for Bladder Cancer Market Forecast
- 10.1 Global Targeted Therapy for Bladder Cancer Forecast by Regions (2023-2028)
- 10.1.1 Global Targeted Therapy for Bladder Cancer Forecast by Regions (2023-2028)
- 10.1.2 Americas Targeted Therapy for Bladder Cancer Forecast
- 10.1.3 APAC Targeted Therapy for Bladder Cancer Forecast
- 10.1.4 Europe Targeted Therapy for Bladder Cancer Forecast
- 10.1.5 Middle East & Africa Targeted Therapy for Bladder Cancer Forecast
- 10.2 Americas Targeted Therapy for Bladder Cancer Forecast by Country (2023-2028)
- 10.2.1 United States Targeted Therapy for Bladder Cancer Market Forecast
- 10.2.2 Canada Targeted Therapy for Bladder Cancer Market Forecast
- 10.2.3 Mexico Targeted Therapy for Bladder Cancer Market Forecast
- 10.2.4 Brazil Targeted Therapy for Bladder Cancer Market Forecast
- 10.3 APAC Targeted Therapy for Bladder Cancer Forecast by Region (2023-2028)
- 10.3.1 China Targeted Therapy for Bladder Cancer Market Forecast
- 10.3.2 Japan Targeted Therapy for Bladder Cancer Market Forecast
- 10.3.3 Korea Targeted Therapy for Bladder Cancer Market Forecast
- 10.3.4 Southeast Asia Targeted Therapy for Bladder Cancer Market Forecast
- 10.3.5 India Targeted Therapy for Bladder Cancer Market Forecast
- 10.3.6 Australia Targeted Therapy for Bladder Cancer Market Forecast
- 10.4 Europe Targeted Therapy for Bladder Cancer Forecast by Country (2023-2028)
- 10.4.1 Germany Targeted Therapy for Bladder Cancer Market Forecast
- 10.4.2 France Targeted Therapy for Bladder Cancer Market Forecast
- 10.4.3 UK Targeted Therapy for Bladder Cancer Market Forecast
- 10.4.4 Italy Targeted Therapy for Bladder Cancer Market Forecast
- 10.4.5 Russia Targeted Therapy for Bladder Cancer Market Forecast
- 10.5 Middle East & Africa Targeted Therapy for Bladder Cancer Forecast by Region (2023-2028)
- 10.5.1 Egypt Targeted Therapy for Bladder Cancer Market Forecast
- 10.5.2 South Africa Targeted Therapy for Bladder Cancer Market Forecast
- 10.5.3 Israel Targeted Therapy for Bladder Cancer Market Forecast
- 10.5.4 Turkey Targeted Therapy for Bladder Cancer Market Forecast
- 10.5.5 GCC Countries Targeted Therapy for Bladder Cancer Market Forecast
- 10.6 Global Targeted Therapy for Bladder Cancer Forecast by Type (2023-2028)
- 10.7 Global Targeted Therapy for Bladder Cancer Forecast by Application (2023-2028)
11 Key Players Analysis
- 11.1 Pfizer
- 11.1.1 Pfizer Company Information
- 11.1.2 Pfizer Targeted Therapy for Bladder Cancer Product Offered
- 11.1.3 Pfizer Targeted Therapy for Bladder Cancer Revenue, Gross Margin and Market Share (2020-2022)
- 11.1.4 Pfizer Main Business Overview
- 11.1.5 Pfizer Latest Developments
- 11.2 Merck KGaA
- 11.2.1 Merck KGaA Company Information
- 11.2.2 Merck KGaA Targeted Therapy for Bladder Cancer Product Offered
- 11.2.3 Merck KGaA Targeted Therapy for Bladder Cancer Revenue, Gross Margin and Market Share (2020-2022)
- 11.2.4 Merck KGaA Main Business Overview
- 11.2.5 Merck KGaA Latest Developments
- 11.3 Roche
- 11.3.1 Roche Company Information
- 11.3.2 Roche Targeted Therapy for Bladder Cancer Product Offered
- 11.3.3 Roche Targeted Therapy for Bladder Cancer Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Roche Main Business Overview
- 11.3.5 Roche Latest Developments
- 11.4 Astellas
- 11.4.1 Astellas Company Information
- 11.4.2 Astellas Targeted Therapy for Bladder Cancer Product Offered
- 11.4.3 Astellas Targeted Therapy for Bladder Cancer Revenue, Gross Margin and Market Share (2020-2022)
- 11.4.4 Astellas Main Business Overview
- 11.4.5 Astellas Latest Developments
- 11.5 Janssen Biotech
- 11.5.1 Janssen Biotech Company Information
- 11.5.2 Janssen Biotech Targeted Therapy for Bladder Cancer Product Offered
- 11.5.3 Janssen Biotech Targeted Therapy for Bladder Cancer Revenue, Gross Margin and Market Share (2020-2022)
- 11.5.4 Janssen Biotech Main Business Overview
- 11.5.5 Janssen Biotech Latest Developments
- 11.6 Bristol-Myers Squibb
- 11.6.1 Bristol-Myers Squibb Company Information
- 11.6.2 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Product Offered
- 11.6.3 Bristol-Myers Squibb Targeted Therapy for Bladder Cancer Revenue, Gross Margin and Market Share (2020-2022)
- 11.6.4 Bristol-Myers Squibb Main Business Overview
- 11.6.5 Bristol-Myers Squibb Latest Developments
- 11.7 Merck & Co.
- 11.7.1 Merck & Co. Company Information
- 11.7.2 Merck & Co. Targeted Therapy for Bladder Cancer Product Offered
- 11.7.3 Merck & Co. Targeted Therapy for Bladder Cancer Revenue, Gross Margin and Market Share (2020-2022)
- 11.7.4 Merck & Co. Main Business Overview
- 11.7.5 Merck & Co. Latest Developments
- 11.8 Gilead Sciences
- 11.8.1 Gilead Sciences Company Information
- 11.8.2 Gilead Sciences Targeted Therapy for Bladder Cancer Product Offered
- 11.8.3 Gilead Sciences Targeted Therapy for Bladder Cancer Revenue, Gross Margin and Market Share (2020-2022)
- 11.8.4 Gilead Sciences Main Business Overview
- 11.8.5 Gilead Sciences Latest Developments
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Targeted Therapy for Bladder Cancer. Industry analysis & Market Report on Targeted Therapy for Bladder Cancer is a syndicated market report, published as Global Targeted Therapy for Bladder Cancer Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Targeted Therapy for Bladder Cancer market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
